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INTRODUCTION
Neoadjuvant chemotherapy (NC) was firstly introduced to 
downsize the locally advanced inoperable breast cancer [1]. 
NC is, now, widely accepted as a treatment for most primary 
breast cancer since its safety and therapeutic efficacy were con-
firmed by prospective randomized studies [2]. A higher rate of 
breast conservation after NC contributed to rapid acceptance 
of NC in operable breast cancer albeit no survival benefit of NC 
was observed over adjuvant chemotherapy [3].
Ultimate aim of most clinical trials is to increase the com-
plete pathologic response (pCR) either by extending the cycles 
of NC or by integrating a novel agent, since a pCR after NC has 
been confirmed as a surrogate marker for improved long-term 
survival [4,5]. Anthracycline-based regimen has been a stan-
dard modality for NC and reported overall response rates of 
69-82% [2,6,7]. Addition of taxane to anthracycline-based reg-
imen further increased the pCR rate as well as overall response 
rate [8,9], but the finding was not uniformly reproduced by 
other studies [10,11]. Integration of taxane was superior to   
anthracycline-based treatment in terms of pCR rate when taxane 
was added in sequential method [8,12], whereas addition of 
taxane into anthracycline concurrently was equivalent with   
anthracycline-based regimens [11]. A result of a recent large 
volume trial indicates that sequential docetaxel-containing 
regimen has no survival benefit over standard anthracycline-
containing regimen in the adjuvant setting in 4,162 women 
[13]. It is not clear whether an increased pCR rate by incorpo-
ration of taxane is the result of its superior therapeutic efficacy 
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Purpose: This study was performed to compare the therapeutic 
efficacy and toxicity of doxorubicin plus docetaxel neoadjuvant 
chemotherapy (NC) with doxorubicin plus vinorelbine NC. Meth-
ods: Fifty-three patients underwent 4 cycles of NC consisted of 
intravenous injection of doxorubicin (50 mg/m
2) plus docetaxel 
(75 mg/m
2) administered every 3 weeks (AD), while 49 patients 
underwent 4 cycles of NC consisted of intravenous injection of 
doxorubicin (50 mg/m
2) and vinorelbine (25 mg/m
2) administered 
every 3 weeks (AN). Response rate and treatment-related toxici-
ties were analyzed by administered chemotherapeutics. Re-
sponse to NC was also analyzed according to clinicobiological 
characteristics of the primary tumors. Results: Clinical response 
was observed in 66% with AN and 81.6% with AD chemother- 
apy. A complete pathologic response (pCR) was confirmed in 6 
patients (11.3%) with AN and in 7 patients (14.3%) with AD after 
the surgery. Response rate was significantly higher in AD com-
pared with AN (p=0.038), but there was no significant difference 
between the two group regard to pCR rate. Breast conserving 
surgery (BCS) was performed in 35.8% of AN group, whereas 20 
patients (40.8%) of AD group underwent BCS. The patients with 
HER2-amplified tumor showed significantly increased response 
to both types of NC. Pathologic complete response was confirmed 
in 9 (39.1%) out of 23 HER2-amplified tumors, whereas only 4 
(5.1%) of 79 HER2-nonamplified tumors showed pathologic com-
plete response. Febrile neutropenia occurred in 22.6% of total 212 
cycles in AN and 38.8% of total 196 cycles in AD. Grade 3/4 neu-
tropenia was observed in 39.6% in AN and 43.9% in AD. Grade 
3 mucositis was observed in 26.4% with AN and in 40.8% with 
AD. Conclusion: There was no significant increase of pCR by AD 
compared with AN. Long-term follow-up results of our study in-
dicate that clinical outcome after NC was significantly associated 
with initial response to NC regardless of therapeutic regimens.
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over other chemotherapeutic agents or the result of extended 
chemotherapy cycles.
We described the results of comparing the therapeutic effi-
cacy of taxane plus anthracycline NC with anthracycline-based 
NC in this report.
 
METHODS
Eligibility criteria
Women aged between 30-58 years with previously untreat-
ed stage II and III breast cancer according to American Joint 
Committee on Cancer (AJCC) 6th edition were eligible for the 
study. The Institutional Review Board approved the study (98-
06), and all patients provided written informed consent. All 
patients were required to have adequate performance status 
(Eastern Cooperative Oncology Group [ECOG] performance 
status ≤1); adequate hematologic (hemoglobin ≥10 g/dL; ab-
solute neutrophil count ≥1.0×10
9/L; and platelets ≥100×10
9/
L), renal (serum creatinine within normal limits), and liver 
functions (ALT, AST, and alkaline phosphatase all ≤1.5×up-
per limit of normal and bilirubin within normal limits); and 
have no evidence of metastatic disease. Patients were excluded 
from the study if there was any evidence of active cardiac dis-
ease and prior history of malignancy at another site.
Treatment 
NC consisted of intravenous injection of doxorubicin (50 
mg/m
2) and docetaxel (75 mg/m
2) administered every 3 weeks 
for a total of 4 cycles (AD) with dexamethasone premedication 
given as 8 mg twice daily beginning 24 hours prior to treatment. 
Antiemetics were administered on the day of NC. 
NC consisted of intravenous injection of doxorubicin (50 
mg/m
2) and vinorelbine (25 mg/m
2) administered every 3 
weeks for a total of 4 cycles (AN). Antiemetics were adminis-
tered on the day of NC. 
Chemotherapy was delayed for 1 week if the absolute neutro-
phil count was less than 1.0×10
9/L or if the platelet count was 
less than 100×10
9/L on the day of planned chemotherapy ad-
ministration. Prophylactic use of the granulocyte colony-stim-
ulating factor was not permitted. In the event of febrile neutro-
penia or nonhematologic National Cancer Institute Common 
Toxicity Criteria (NCI-CTC version 2) grade 3/4 toxicity ex-
cluding alopecia, subsequent chemotherapy was administered 
at a 25% dose reduction of both chemotherapeutics in each 
group. Complete blood count was monitored every week for 
the 1st cycle, thereafter every 3 weeks unless the patient expe-
rienced fever.
All patients underwent curative surgery within 30 days after 
the completion of NC. Operative specimens were reviewed by 
the pathologist for nodal status and pathologic response. The 
same regimen of chemotherapy was administered for 2 cycles 
after the operation if the primary tumor responded to the NC 
(PR and pCR). In cases with stable disease (SD), 4 cycles of pa-
clitaxel (225 mg/m
2) was administered every 3 weeks postop-
eratively for node-positive patients whereas 6 cycles of cyclo-
phosphamide (600 mg/m
2 intravenously on day 1), methotrex-
ate (40 mg/m
2 intravenously on day 1) and 5FU (600 mg/m
2 
intravenously on day 1) was administered every 3 weeks for 
node-negative patients. Radiation therapy to the entire chest 
wall and supraclavicular area began within 4 weeks after the last 
cycles of postoperative chemotherapy if indicated. The breast 
was treated to 5,000 cGy with conventional fraction of 180-200 
cGy/day. A boost was administered to the tumor excision site 
to bring the total dose to 6,050 cGy. Clinical evaluations were 
performed every 3 months for 1 year and every 6 months there-
after. 
Response evaluation
The primary end point of this study was the response rates 
to the each NC. Patients were evaluable for tumor response if 
they received the planned 4 cycles of chemotherapy. Tumor 
response was determined by clinical assessment of bidimen-
sionally measurable disease using standard response criteria. 
Pretreatment tumor assessment, including a physical examina-
tion, mammography and ultrasonography, was obtained be-
fore the beginning of the NC. Clinical tumor response was as-
sessed by palpation prior to each cycle and by imaging study 
at every 2 cycles of NC measuring maximum perpendicular 
diameter of primary tumor. The clinical response of bidimen-
sionally measurable lesion was classified according to World 
Health Organization criteria. The cCR was defined as the dis-
appearance of all known disease and a clinical partial response 
(cPR) was defined as a 50% or greater decrease in size of the 
primary lesion. Progressive disease was defined as a 25% or 
greater increase in size of the primary tumor. Stable disease rep-
resented a less than 50% decrease or a less than 25% increase 
in size of the primary tumor. The pCR was defined as no resid-
ual tumor cells in the breast, and no nodal involvement by in-
vasive cancer in surgically removed specimens. The cases with 
in situ cancer component without viable invasive cancer cells 
were regarded as a pCR.
Statistical evaluation
This study is non-inferiority clinical trials comparing of pri-
mary endpoint which is overall response rate of each group. We 
used optimal two-stage design with 80% power (20% alpha 
error) and 10% expected dropout rate for calculation of sam-
ple size. We hypothesized that AN group is non-inferior than NeoadjuvantChemotherapywithDoxorubicinPlusVinorelbine 131
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AD group when the difference of overall response rate is less 
than 20%. We expected the pathologic complete response (pCR) 
rate of both AD and AN neoadjuvant chemotherapy as 15% 
(5-15%) and overall response rate (pCR+PR) of both arms as 
70% (range, 60-80%). 
Around 95 subjects per each group were needed to evaluate 
the equivalent therapeutic efficacy of AN chemotherapy to AD 
chemotherapy. Statistical comparison of efficacy and safety be-
tween two groups was performed by chi-square test or Fisher’s 
exact test. Survival analysis was performed by Kaplan-Meier 
method. We used SPSS software (SPSS Inc., Chicago, USA) ver-
sion 15.0 for statistical analysis. 
RESULTS
Between January 1998 and December 2005, total of 102 pa-
tients were enrolled to the study. The study was closed at De-
cember 2005 because of slow enrollment although the planned 
number of patients had not been enrolled. The median age was 
41 years for AN and 43 for AD patients (range, 30-58). Medi-
an pretreatment tumor size was 6 cm (range, 3-11 cm). Per-
formance score of the patients was 0 in 81% and 1 in 19% by 
ECOG criteria. Forty-six patients (45.1%) had clinically nega-
tive axillary lymph node while 56 patients (54.9%) had clini-
cally positive node before NC (Table 1). Most of patients had 
invasive ductal carcinoma while 4 patients had invasive lobu-
lar carcinoma. Estrogen receptor was positive in 55 patients 
(53.9%). HER2 was amplified in 23 (22.5%). All patients were 
assessable for both toxicity and efficacy. 
Toxicity and compliance to chemotherapy
All the patients underwent the planned cycles of AD or AN 
neoadjuvant chemotherapy. Febrile neutropenia occurred in 
22.6% (48 events) of total 212 cycles in AN and 38.8% (76 
events) of total 196 cycles in AD. Grade 3/4 neutropenia was 
observed in 39.6% of total 212 cycles in AN and 43.9% of total 
196 in AD (Table 2). No grade 3/4 anemia or thrombocytope-
nia was observed in both groups. Hematologic toxicities had a 
tendency to be increased in AD chemotherapy. Incidence of 
febrile neutropenia was significantly increased in AD com-
pared with AN (p=0.047). Grade 3 mucositis was observed 
in 14 patients (26.4%) with AN and in 20 patients (40.8%) with 
AD (Table 2). No clinical cardiac toxicity was observed in both 
groups. Reversible alopecia was observed in all patients.
Other observed toxicities were grade 3 abdominal pain (4 
with AN4, 5 with AD4). Less frequent toxicities were diarrhea, 
skin eruption and ALT/AST elevation but all were within grade 
1/2 in both groups by NCI-CTC criteria. Mean relative dose 
intensity was 0.76 for AD and 0.84 for AN. Some patients re-
fused to reduce subsequent dose reduction after febrile neutro-
penia, thus delayed administration of NC was done in these 
cases.
Efficacy
Pathologic response was assessable for all patients. Clinical 
Table 1. Clinical characteristics of studied patients 
AN #4 (n=53)  
No. (%)
AD #4 (n=49)  
No. (%)
Age (yr)* 41 (30-58) 42 (32-56)
T stage
   T1
   T2
   T3
 
20 (37.7)
27 (50.9)
  6 (11.4)
 
19 (38.8)
23 (46.9)
  7 (14.3)
Clinical nodal stage
   Negative
   Positive
 
27 (50.9)
26 (49.1)
 
19 (38.8)
30 (61.2)
Histology
   IDC
   ILC
 
51 (96.2)
2 (3.8)
 
47 (95.9)
 2 ( 4.1)
Histologic grade
   1-2
   3
 
26 (49.1)
27 (50.9)
 
22 (44.9)
27 (55.1)
Estrogen receptor status
   Positive
   Negative
 
29 (54.7)
24 (45.3)
 
26 (53.1)
23 (46.9)
HER2 by FISH
   Amplified
   Not-amplified
 
11 (20.7)
42 (79.3)
 
12 (24.5)
37 (75.5)
AN=doxorubicin plus vinorelbine; AD=doxorubicin plus docetaxel; IDC= 
invasive ductal carcinoma; ILC=invasive lobular carcinoma; FISH=fluo-
rescence in situ hybridization.
*Median (range).
Table 2. Toxicity profiles
AN #4 (n=53) 
No. (%)
AD #4 (n=49) 
No. (%) p-value
Total cycles #212 #196
Neutropenia (Grade 3/4) 
   at any cycle
84 (39.6) 90 (45.9) 0.068
Febrile neutropenia at any cycle 48 (22.6) 76 (38.8) 0.047
Mucositis (G 3) 14 (26.4) 20 (40.8) 0.058
AN=doxorubicin plus vinorelbine; AD=doxorubicin plus docetaxel.
Table 3. Response rates to AN #4 or AD #4
AN #4 (n=53) 
No. (%)
AD #4 (n=49) 
No. (%)
p-value
pCR   6 (11.3)   7 (14.3) 0.159
PR 29 (54.7) 33 (67.3) 0.076
SD 18 (34.0)   9 (18.4) 0.038
Breast conservation 19 (35.8) 20 (40.8) 0.472
AN=doxorubicin plus vinorelbine; AD=doxorubicin plus docetaxel; 
pCR=complete pathologic response; PR=partial response; SD=stable 
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response was assessed before surgery after the completion of 
the last NC by physical examination, mammography, and ul-
trasonography. 
Clinical response was observed in 66% with AN and 81.6% 
with AD chemotherapy (Table 3). A complete disappearance 
of primary tumor with negative axillary lymph node was con-
firmed in 6 patients (11.3%) with AN and in 7 patients (14.3%) 
with AD after the surgery. Overall response rate was signifi-
cantly higher in AD compared with AN (p=0.038), but there 
was no significant difference between the two group regard to 
pathologic complete response rate.
Nineteen patients (35.8%) of AN group underwent breast 
conserving surgery (BCS) whereas 20 patients (40.8%) of AD 
group underwent BCS. 
Relationship between response to chemotherapy  
and biologic variables
The data from the 2 groups were merged and analyzed to as-
sess the predictive factors to NC. The patients with HER2-am-
plified tumor showed significantly increased response to both 
type of NC. Pathologic complete response was confirmed in 9 
(39.1%) out of 23 HER2-amplified tumors, whereas only 4 (5.1%) 
of 79 HER2-nonamplified tumors showed pathologic com-
plete response (Table 4). Response rate was also significantly 
increased in node-negative tumors. Hormone receptor status 
or histologic grade was not associated with tumor response to 
NC. There was a tendency that pCR rate increased in smaller 
tumors.
Clinical outcome according to the response to NC
During the median follow-up period of 38 months (range, 
8-70 months), 39 patients (38.2%) had systemic recurrence. 
Only one patient with pCR had systemic recurrence whereas 
30.7% of PR and 70.4% of SD had systemic recurrence (Table 
5). Patients who had pCR after NC showed significantly higher 
disease free survival rate compared to the patients with resid-
ual disease after NC (p<0.001) (Figure 1). 
DISCUSSION
Integration of docetaxel into anthracycline-based chemo-
therapy showed a promising result in the management of met-
astatic breast cancer [14]. However, most of neoadjuvant trial 
incorporating docetaxel into anthracycline-based regimen did 
not significantly improve clinical outcome despite their increased 
clinical response rate compared with anthracycline-based reg-
imens [10,12]. In our study, overall response rate to AD was 
superior to AN but pCR rate was not different between the two 
Table 4. Response to chemotherapy according to clinical-biological 
characteristics
pCR  
No. (%)
PR  
No. (%)
SD  
No. (%)
Total  
No.  p-value
T stage
   T1
   T2
   T3
  
10 (25.6)
  3 (11.3)
  0 (18.7)
  
28 (71.8)
32 (60.4)
  2 (12.5)
  
1 (2.6)
15 (28.3)
11 (68.8)
  
  39
  50
  13
0.064
Clinical nodal stage
   Negative
   Positive
 
10 (21.7)
3 (5.3)
 
32 (69.5)
30 (53.6)
 
4 (8.8)
23 (41.1)
 
  46
  56
0.014
Histologic grade
   1-2
   3
 
3 (6.3)
10 (18.5)
 
30 (62.5)
32 (59.3)
 
15 (31.2)
12 (22.2)
 
  48
  54
0.332
Estrogen receptor status
   Positive 
   Negative
 
  6 (10.9)
  7 (14.9)
 
35 (63.6)
27 (57.4)
 
14 (25.5)
13 (27.7)
 
  55
  47
0.446
HER2 by FISH
   Amplified
   Not-amplified
   Total
 
  9 (39.1)
4 (5.1)
13 (12.7)
 
11 (47.8)
51 (64.5)
62 (60.8)
 
  3 (13.1)
24 (30.4)
27 (26.5)
 
  23
  79
102
0.007
pCR=complete pathologic response; PR=partial response; SD=stable 
disease; FISH=fluorescence in situ hybridization. 
Table 5. Distant disease-free survival according to the response to neo-
adjuvant chemotherapy
Distant DFS* No. (%) Total No. (%) p-value
pCR 12 (92.3) 13 <0.001
PR 43 (69.3) 62
SD   8 (29.6) 27
DFS=disease-free survival; pCR=complete pathologic response; PR= 
partial response; SD=stable disease.
*Median follow-up period of 38 months (range, 8-70 months).
C
u
m
 
s
u
r
v
i
v
a
l
Months
Disease-free survival
  0.00  10.00  20.00  30.00  40.00  50.00  60.00  70.00  80.00
1.0
0.8
0.6
0.4
0.2
0.0
Figure 1. Disease-free survivals according to response to doxorubicin 
and vinorelbine neoadjuvant chemotherapy.
SD=stable disease; PR=partial response; pCR=complete pathologic 
response. 
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groups. A recent report of clinical trial with longer follow-up 
supports the no relative benefit of AD over doxorubicin plus 
cyclophosphamide NC in respect of pCR rate and overall sur-
vival [11]. Our result well coincides with aforementioned oth-
er large volume studies. In contrast, sequential use of docetax-
el after doxorubicin plus cyclophosphamide NC significantly 
increased pCR rate in NSABP B27 trial [12]. Longer duration 
of NC might affect the increase of pCR but results of other stud-
ies support the additional effect of sequential docetaxel [8,15]. 
It is not clear at this stage whether increased pCR rate is a result 
of docetaxel effect or extended duration of NC. 
Primary goal of NC is to achieve pCR since patients achiev-
ing pCR NC have better long-term survival than others who 
failed to respond to NC irrespective of chemotherapeutic agents 
[4,12]. The patients achieving pCR showed far better clinical 
outcome in our study. However, a recent retrospective analysis 
reported that clinical outcome is variable even among the pa-
tients who had pCR to NC [16]. The investigators suggested 
that a non-negligible risk of relapse remains even after pCR to 
NC in patients with large tumor size and clinical nodal involve-
ment at baseline. Late analysis of NSABP B27 identified that 
clinical outcome of patients with residual disease after NC is 
heterogeneous and patients with negative lymph node have 
8-year disease-free survival of 70% compared 40% of patients 
with positive lymph node [12]. Long-term results of the two 
large volume clinical trials suggest that it would be more im-
portant to discriminate the poor prognostic patients who need 
more aggressive systemic treatment after NC. 
Response to the NC was significantly associated with HER2 
status and initial nodal status in our study regardless of chemo-
therapy regimens. We already reported that response to anthra-
cycline-based NC is significantly associated with HER2 ampli-
fication [17]. Remarkable association between anthracycline 
sensitivity and HER2 amplification have been investigated by 
many studies [18-20]. In our study, response to NC was better 
in smaller tumors although the association was not statistically 
significant. The finding together with increased response rate 
in node-negative patients indicates that NC is more effective 
in early stage rather than advanced breast cancers.
One of merits of NC is an increased opportunity for breast 
preservation. There was no difference in breast conserving rate 
between the two groups in our study. Breast conserving rate 
was less than 40% in our study albeit the overall response rate 
to NC was 70%. Large proportion of advanced disease might 
contribute to the lower rate of breast conservation in our study. 
In NSABP B27 trial, 68% of patients who underwent NC had 
BCS whereas 60% of control group had BCS [12]. If the study 
population was well balanced, significant proportion of indi-
viduals who underwent NC might be a candidate for BCS at 
initial stage in NSABP B27 trial. It seems to be reasonable to 
recommend NC mostly for the individuals who seem to be im-
possible to preserve their breast at initial presentation.
In summary, there was no significant increase of pCR by AD 
compared with AN. Long-term follow-up results of our study 
indicated that clinical outcome after NC was significantly as-
sociated with initial response to NC regardless of therapeutic 
regimens.
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